Advanced search
Publication Cover
Expert Review of Vaccines Volume 3, 2004 - Issue 6
Submit an article Journal homepage
82
Views
12
CrossRef citations to date
0
Altmetric
Review

Intracerebroventricular passive immunization in transgenic mouse models of Alzheimer’s disease

Neelima B Chauhan University of Illinois at Chicago, Department of NeuroAnesthesiology, Chicago, IL, USA. [email protected]
&
George J Siegel Loyola University Medical Center, Department of Neurology and Department of Cell Biology, Neurobiology and Anatomy, Maywood, IL 60153, USA. [email protected]
Pages 717-725 | Published online: 09 Jan 2014

References

  • Kang J, Lemaire HG, Unterbeck A et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325(6106), 733–736 (1987).
  • Haass C, Koo EH, Mellon A et al. Targeting of cell-surface 13-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments. Nature 357 (6378), 500–503 (1992).
  • Selkoe DJ. Normal and abnormal biology of the 13-amyloid precursor protein. Ann. Rev. Neurosd. 17, 489–517 (1994).
  • Siegel GJ, Chauhan NB, Karczmar AG. Linking amyloid and tau biology in Alzheimer's disease. In: The Rise of Research on the Cholinergic Central Nervous System. Karczmar AG (Ed.). Kluver Publishing Co., NY, USA. In press.
  • Takashima A, Honda T, Yasutake K et al. Activation of tau protein kinase I/glycogen synthase kinase-313 by amyloid-13 peptide (25–35) enhances phosphorylation of tau in hippocampal neurons. Neurosci. Res. 31(4), 317–323 (1998).
  • Games D, Adams D, Alessandrini R et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F amyloid precursor protein. Nature 373(6514), 523–527 (1995).
  • Duff K, Eckman C, Zehr C, Yu X et al. Increased amyloid-1342 (43) in brains of mice expressing mutant presenilin 1. Nature 383(6602), 710–713 (1996).
  • Hsiao K, Chapman P, Nilsen S et al. Correlative memory deficits, AB elevation, and amyloid plaques in transgenic mice. Science 274(5284), 99–102 (1996).
  • Borchelt DR, Ratovitski T, van Lare et al. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19(4), 939–945 (1997).
  • Tomidokoro Y, Harigaya Y, Matsubara E et al. Brain A13 amyloidosis in APPsw mice induces accumulation of presenilin-1 and tau. Path& 194(4), 500–506 (2001).
  • Chauhan NB, Siegel GJ. Effect of PPF and ALCAR on the induction of NGF- and p75-mRNA and on APP processing in Tg2576 brain. Neurochern. Int. 43(3), 225–233 (2003).
  • Chauhan NB, Feinstein DL, Siegel, GJ. Propentofylline attenuates tau phosphorylation in Alzheimer's Swedish mutant model Tg2576. Neuropharrnacology (2004). In press.
  • Lewis J, Dickson DVV, Lin WL et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Sdence 293(5534), 1487–1491 (2001).
  • Gotz J, Chen F, Barmettler R et al. Tau filament formation in transgenic mice expressing P301L tau. J. Biol. Chem. 276(1), 529–534 (2001).
  • Selkoe DJ, Lansbury PT. Biochemistry of Alzheimer's and prion diseases. In: Basic Neurochemistry: Molecular; Cellular and Medical Aspects. Siegel GJ, Agranoff BW, Albers RW, Fisher SK, Uhler MD (Eds). Lippincott-Raven Press, PA, USA, 949–968 (1999).
  • Ferrer I, Boada Rovira M, Sanchez Guerra ML et al. Neuropathology and pathogenesis of encephalitis following amyloid-13 immunization in Alzheimer's disease. Brain Pathol. 14(1), 11–20 (2004).
  • Oddo S, Caccamo A, Kitazawa M et al. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol. Aging24 (8), 1063–1070 (2003).
  • Simons M, Keller P, De Strooper B et al. Cholesterol depletion inhibits the generation of 13-amyloid in hippocampal neurons. Proc. Natl Acad. Sci. USA 95 (11), 6460–6464 (1998).
  • Simons M, Keller P, Dichgans J et al. Cholesterol and Alzheimer's disease: is there a link? Neurology57(6), 1089–1093 (2001).
  • Chauhan NB, Siegel GJ. Intracerebroventricular passive immunization with anti-AB antibody in Tg2576. j Neurosd. Res. 74(1), 142–147 (2003).
  • Atwood CS, Perry G, Smith MA. Cerebral hemorrhage and amyloid-B. Science 299(5609), 1014 (2003).
  • Chauhan NB, Siegel GJ. Reversal of amyloid-13 toxicity in Alzheimer's disease model Tg2576 by intraventricular anti-amyloid-13 antibody. J. Neurosci. Res. 69(1), 10–23 (2002).
  • Smith MA, Casadesus G, Joseph JA et al. Amyloid-13 and tau serve antioxidant functions in the aging and Alzheimer brain. Free Radic. Biol. Med. 33(9), 1194–1199 (2002).
  • Kuo YM, Emmerling MR, Bisgaier CL et al. Elevated low-density lipoprotein in Alzheimer's disease correlates with brain AB 1–42 levels. Biochern. Biophys. Res. C01771771117. 252(3), 711–715 (1998).
  • Morgan D, Gitter BD. Evidence supporting a role for anti-AB antibodies in the treatment of Alzheimer's disease. Neurobiol. Aging 25(5), 605–608 (2004).
  • Alberts AW. Discovery, biochemistry and biology of lovastatin. Am. J. Cardiology 62(15), 10J-15J (1988).
  • Mukherjee A, Hersh LB. Regulation of amyloid-3-peptide levels by enzymatic degradation. J. Alzheirners Dis. 4 (5), 341–348 (2002).
  • Scherzer CR, Offe K, Gearing M et al. Loss of apolipoprotein E receptor LR11 in Alzheimer's disease. Arch. NeuroL 61, 1200–1205 (2004).
  • Solomon B, Koppel R, Hanan E et al. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer 13-amyloid peptide. Proc. Nat] Acad. Sci. USA 93(1), 452–455 (1996).
  • Solomon B, Koppel R, Frankel D et al. Disaggregation of Alzheimer 13-amyloid by site-directed mAb. Proc. Nat] Acad. Sci. USA 94(8), 4109–4112 (1997).
  • Frenkel D, Katz 0, Solomon B. Immunization against Alzheimer's 13-amyloid plaques via EFRH phage administration. Proc. Nat] Acad. Sci. USA 97(21), 11455–11459 (2000).
  • Schenk D, Barbour R, Dunn W et al. Immunization with amyloid-13 attenuates Alzheimer disease-like pathology in the PDAPP mouse. Nature 400(6740), 173–177 (1999).
  • Janus C, Pearson J, McLaurin J et al. A13 peptide immunization reduces behavioral impairment and plaques in a model of Alzheimer's disease. Nature 408 (6815), 979–982 (2000).
  • Morgan D, Diamond DM, Gottschall PE et al. A13 peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408 (6815), 982–985 (2000).
  • Arendash GW, Gordon MN, Diamond DM et al. Behavioral assessment of Alzheimer's transgenic mice following long-term A13 vaccination: task specificity and correlations between A13 deposition and spatial memory. DNA Cell Biol. 20(11), 737–744 (2001).
  • Das P, Murphy MP, Younkin LH et al. Reduced effectiveness of AI31-42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol. Aging22 (5), 721–727 (2001).
  • Sigurdsson EM, Scholtzova H, Mehta PD et al. Immunization with a nontoxic/nonflbrillar amyloid-13 homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am. j Pathol. 159 (2), 439–447 (2001).
  • Frenkel D, Kariv N, Solomon B. Generation of autoantibodies towards Alzheimer's disease vaccination. Vaccine 19 (17-19), 2615–2619 (2001).
  • Lemere CA, Maron R, Spooner ET et al. Nasal A13 treatment induces anti-A13 antibody production and decreases cerebral amyloid burden in PDAPP mice. Ann. NY Acad. Sci. 920,328-331 (2000).
  • Lemere CA, Spooner ET, Leverone JF et al. Intranasal immunotherapy for the treatment of Alzheimer's disease: Escherichia coil LT and LT(R192G) as mucosal adjuvants. NeurobioL Aging23(6), 991–1000 (2002).
  • Nicolau C, Greferath R, Balaban 'FS et al. A liposome-based therapeutic vaccine against 13-amyloid plaques on the pancreas of transgenic NORBA mice. Proc. Nat] Acad. Sci. USA 99(4), 2332–2337 (2002).
  • Zhang J, Wu X, Qin C et al. A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and 13-amyloid plaques in a mouse model of Alzheimer's disease. NeurobioL Dis. 14(3), 365–379 (2003).
  • Spooner ET, Desai RV, Mod C et al. The generation and characterization of potentially therapeutic A13 antibodies in mice: differences according to strain and immunization protocol. Vaccine 21(3–4), 290–297 (2002).
  • Karkos J. Immunotherapy of Alzheimer's disease. Results of experimental investigations and treatment of perspectives. Fortschr. Neurol. Psychiatr. 72(4), 204–219 (2004).
  • Lue LF, Walker DG. Modeling Alzheimer's disease immune therapy mechanisms: interactions of human postmortem microglia with antibody-opsonized amyloid-13 peptide. .1. Neurosci. Res. 70(4), 599–610 (2002).
  • Mitrasinovic OM, Murphy GM Jr. Microglial overexpression of the MCSF receptor augments phagocytosis of opsonized A13. Neurobiol. Aging 24(6), 807–815 (2003).
  • Sigurdsson EM, Wisniewski T, Frangione B. A safer vaccine for Alzheimer's disease? NeurobioL Aging 23 (6), 1001–1008 (2002).
  • Bacskai BJ, Kajdasz ST, McLellan ME et al. Non-Fc-mediated mechanisms are involved in clearance of amyloid-13 in vivo by immunotherapy. j Neurosci. 22(18), 7873–7878 (2002).
  • Orgogozo JM, Gilman S, Dartigues JF et al. Subacute meningoencephalitis in a subset of patients with AD after A1342 immunization. Neurology 61(1), 46–54 (2003).
  • Nicoll JA, Wilkinson D, Holmes C et al. Neuropathology of human Alzheimer's disease after immunization with amyloid-13 peptide: a case report. Nature Med. 9(4), 448–452 (2003).
  • Monsonego A, Zota V, Karni A et al. Increased T-cell reactivity to amyloid-13 protein in older humans and patients with Alzheimer's disease. .1. Clin. Invest. 11(3), 415–422 (2003).
  • Cribbs DH, Ghochikyan A, Vasilevko V et al. Adjuvant-dependent modulation of Thl and Th2 responses to immunization with 13-amyloid. Int IrnmunoL 15(4), 505–514 (2003).
  • McGeer PL, McGeer E. Is there a future for vaccination as a treatment for Alzheimer's disease? NeurobioL Aging 24 (3), 391–395 (2003).
  • Pfeifer M, Boncristiano S, Bondolfi L et al. Cerebral hemorrhage after passive anti-A13 immunotherapy. Science 298 (5597), 1379 (2002).
  • Munch G, Robinson SR. Potential neurotoxic inflammatory responses to A13 vaccination in humans. .1. Neural. Transrn. 109(7–8), 1081–1087 (2002).
  • Hock C, Konietzko U, Papassotiropoulos A et al. Generation of antibodies specific for 13-amyloid by vaccination of patients with Alzheimer's disease. Nature Med. 8 (11), 1270–1275 (2002).
  • Hock C, Konietzko U, Streffer JR et al. Antibodies against 13-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38(4), 547–554 (2003).
  • Bard F, Cannon C, Barbour R et al. Peripherally administered antibodies against amyloid 13-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer's disease. Nature Med. 6(8), 916–919 (2000).
  • DeMattos RB, Bales KR, Cummins DJ et al. Peripheral anti-A13 antibody alters CNS and plasma A13 clearance and decreases brain A13 burden in a mouse model of Alzheimer's disease. Proc. Nat] Acad. Sci. USA 98(15), 8850–8855 (2001).
  • Dodart JC, Bales KR, Gannon KS et al. Immunization reverses memory deficits without reducing brain A13 burden in Alzheimer's disease model. Nature Neurosci. 5(5), 452–457 (2002).
  • Furlan R, Brambilla E, Sanvito F et al. Vaccination with amyloid-13 peptide induces autoimmune encephalomyelitis in C57/BL6 mice. Brain 126(2), 285–291 (2003).
  • Wilcock DM, DiCarlo G, Henderson D et al. Intracranially administered anti-A13 antibodies reduce 13-amyloid deposition by mechanisms both independent of and associated with microglial activation. .1. Neurosci. 23(9), 3745–3751 (2003).
  • Solomon B. Immunotherapeutic strategies for prevention and treatment of Alzheimer's disease. DNA Cell Biol. 20(11), 697–703 (2001).
  • Lemere CA, Spooner ET, LaFrancois J al Evidence for peripheral clearance of cerebral A13 protein following chronic, active A13 immunization in PSAPP mice. Neurobiol. Dis. 14(1), 10–18 (2003).
  • Bacskai BJ, Kajdasz ST, Christie RH et al. Imaging of amyloid-13 deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nature Med. 7(3), 369–372 (2001).
  • Farr SA, Banks WA, Uezu K et al. Antibody to 13-amyloid protein increases acetylcholine in the hippocampus of 12 month SAMP8 male mice. Life Sci. 73(5), 555–562 (2003).
  • Lombardo JA, Stern EA, McLellan ME et al. Amyloid-13 antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. J Neurosci. 23(34), 10879–10883 (2003).
  • Chauhan NB, Siegel GJ, Lichtor T. Distribution of intraventricularly administered anti-amyloid-13 peptide (A13) antibody in the mouse brain. J Neurosci. Res. 66(2), 231–235 (2001).
  • Chauhan NB, Siegel GJ. Efficacy of anti-A13 antibody isotypes used for intracerebroventricular immunization in TgCRND8. Neurosd. Lett. (2004). In press.
  • Chauhan NB, Siegel GJ, Lichtor T. Effect of age on the duration and extent of amyloid plaque reduction and microglial activation after injection of anti-A13 antibody into the third ventricle of TgCRND8 mice. J. Neurosa Res. (2004). In press.
  • Sainte-Rose C, Cinalli G, Roux FE et al. Management of hydrocephalus in pediatric patients with posterior fossa tumors: the role of endoscopic third ventriculostomy. J Neurosurg. 95(5), 791–797 (2001).
  • Siomin V, Cinalli G, Grotenhuis A et al. Endoscopic third ventriculostomy in patients with cerebrospinal fluid infection and/or hemorrhage. J Neurosurg. 97(3), 519–524 (2002).
  • Poca MA, Mataro M, Del Mar Matarin M et al. Is the placement of shunts in patients with idiopathic normal-pressure hydrocephalus worth the risk? Results of a study based on continuous monitoring of intracranial pressure. J Neurosurg. 100(5), 855–866 (2004).
  • Svennerholm L, Brane G, Karlsson I et al. Alzheimer's disease — effect of continuous intracerebroventricular treatment with GM1 ganglioside and a systematic activation programme. Dement. Geriatr. Cogn. Disord. 14(3), 128–136 (2002).
  • Elices MJ. Natalizumab. Elan/Biogen. Curr. Opin. Investig. Drugs 4(11), 1354–1362 (2003).
  • Ghosh S. Therapeutic value of a-4 integrin blockade in inflammatory bowel disease: the role of natalizumab. Expert Opin. Biol. Ther. 3(6), 995–1000 (2003).
  • Elices et al. Natalizumab: AN 100226, anti- 4a integrin monoclonal antibody. Drugs R D5(2), 102–107 (2004).
  • Pels H, Schulz H, Schlegel U, Engert A. Treatment of CNS lymphoma with the anti-CD20 antibody rituximab: experience with two cases and review of the literature. Onkologie 26 (4), 351–354 (2003).
  • Chauhan NB, Siegel GJ, Feinstein DL. Effects of lovastatin and pravastatin on amyloid processing and inflammatory response in TgCRND8 brain. Neurochern. Res. 29(10), 1897–1911 (2004).

Websites

  • National Institute on Ageing www.nia.nih.gov/ (Accessed November, 2004).
  • Alzheimer Research Forum www.alzforum.org/dis/abo/default.asp (Accessed November, 2004).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.